跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 175 条关于
“CD103”
全部
175
临床试验
87
药物
78
机构
0
资讯
10
2个月前
Tissue-Resident Memory T Cells Explain Site-Specific Relapse in Atopic Dermatitis
去年
Oncolytic Virus-Immune Checkpoint Inhibitor Combinations Show Promise in Melanoma Treatment
3个月前
Stanford Researchers Engineer Tissue-Resident NK Cells That Infiltrate and Slow Solid Tumors in Mice
去年
Intranasal COVID-19 Vaccines Show Superior Mucosal Immunity and Long-Term Protection in Preclinical Studies
去年
CD163+ Tumor-Associated Macrophages Linked to Improved Nivolumab Outcomes in Metastatic Renal Cell Carcinoma
去年
Phase 1/2 Study Reports Final Results for CD123-Targeted Tagraxofusp in Relapsed/Refractory Myelofibrosis
去年
Spica Therapeutics Secures €1 Million VLAIO Grant to Advance Anti-CD163 Monoclonal Antibody for Cancer Treatment
8个月前
Phase 1/2 Trial Demonstrates Safety and Efficacy of Autologous CD133+ Stem Cell Therapy for Asherman Syndrome
9个月前
ProBioGen Partners with Spica Therapeutics to Advance First-in-Class Anti-CD163 Antibody ST101 for Cancer Immunotherapy
27天前
Orum Therapeutics Announces U.S. FDA Clearance of IND for ORM-1153, a First-in-Class CD123-GSPT1 Degrader-Antibody Conjugate